Navigation path

RESMALCHIP


Malaria

Development of a Malaria-Resistant DNA Chip as a Public Health Tool for the Management of Plasmodium Falciparum Malaria Drug Resistance
Framework programme:
5
Project number:
QLK2-CT-2002-01503
EC contribution:
€ 1 292 000
Duration:
36 months
Type:
RS
Starting date:
1 January 2003

Keywords: DNA chips; malaria; drug resistance

Summary:

This project aims at evaluating a newly developed DNA micro array for drug resistance monitoring in affected areas. Results will allow the dynamics of drug resistance to be captured and to forecast its development by establishing a community-based genetic resistance index, providing tools for rational and evidence-based decisions on the optimal use of drugs. The relationship between in vivo drug sensitivity and in vitro susceptibility to several anti-malarials, and the prevalence of multiple SNPs providing correlates for clinical resistance will be assessed. Sequencing will identify additional informative codons.

Problem:

The genetic diversity of malaria parasites is a major obstacle in the development of rational control strategies against this poverty related disease. Increase of health threatening drug resistance must be monitored and prevented to protect introduced drugs.

Aim:

The aims of this project are:

  1. to develop a sensitive, standardised tool for large-scale molecular epidemiological studies on Plasmodium falciparum drug resistance based on a DNA chip detecting SNPs
  2. to further document nucleotide polymorphism of genes associated with drug resistance in field samples and develop novel markers
  3. to establish a genetic resistance index (GRI) in several malaria endemic sites all over the world
  4. to coordinate efforts of European molecular epidemiologists working in different field sites to achieve a worldwide multi-locus survey of genes involved in resistance against major anti-malarial drugs
  5. to transfer innovative, high throughput technology, and provide training to malaria endemic countries to establish efficient tools for drug policy decision-making.
[+] Read More